Your browser doesn't support javascript.
loading
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence.
Olivera, Pablo; Danese, Silvio; Pouillon, Lieven; Bonovas, Stefanos; Peyrin-Biroulet, Laurent.
Afiliação
  • Olivera P; Gastroenterology Section, Department of Internal Medicine, CEMIC, Buenos Aires, Argentina.
  • Danese S; Department of Biomedical Sciences, Humanitas University, Milan, Italy; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy.
  • Pouillon L; INSERM U954 and Department of Hepatogastroenterology, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France; Imelda GI Clinical Research Centre, Imeldaziekenhuis Bonheiden, Bonheiden, Belgium.
  • Bonovas S; Department of Biomedical Sciences, Humanitas University, Milan, Italy; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy.
  • Peyrin-Biroulet L; INSERM U954 and Department of Hepatogastroenterology, Nancy University Hospital, University of Lorraine, Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com.
Dig Liver Dis ; 51(3): 327-334, 2019 03.
Article em En | MEDLINE | ID: mdl-30555013
BACKGROUND: Biologics against tumor necrosis factor (anti-TNF) have dramatically changed the management of moderate-to-severe ulcerative colitis (UC). In pivotal clinical trials, golimumab showed efficacy as induction and maintenance therapy in anti-TNF naïve UC patients. However, confirmatory data on effectiveness in the real world setting are needed. AIM: to summarize recent evidence on the effectiveness of golimumab in observational real-world studies. METHODS: A literature search was conducted using Medline, Embase, and congresses databases for English language articles or abstracts on the effectiveness of golimumab published between January 1, 2014 and May 15, 2018. Pooled short-term (6-14 weeks) and mid- and long-term (24-54 weeks) clinical response and remission rates were calculated. RESULTS: 24 abstracts were included; of those 8 were published full-text articles and 16 were abstracts from medical conferences. Overall, pooled short-term clinical response and remission rates were 59.3% (range 35-85.5%; 13 studies; 1429 patients) and 35.9% (range 14-51.7%; 9 studies; 666 patients), respectively. Pooled mid- and long-term clinical response and remission rates were 60.3% (range 37.1-89.5%; 4 studies; 356 patients) and 39.2% (range 12-84%; 8 studies; 822 patients), respectively. CONCLUSIONS: Results: of observational studies confirm that golimumab is an effective therapy for UC in clinical practice.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite Ulcerativa / Fator de Necrose Tumoral alfa / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Observational_studies / Systematic_reviews Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Dig Liver Dis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Argentina País de publicação: Holanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite Ulcerativa / Fator de Necrose Tumoral alfa / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Observational_studies / Systematic_reviews Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Dig Liver Dis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Argentina País de publicação: Holanda